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One of the major problems in the treatment of glaucoma is the limited therapeutic effect (6 to 8 hours) of pilocarpine eye drops. Consequently many attempts have been made to prolong the hypotensive effect of pilocarpine. Increase in concentration of pilocarpine above 4 % has failed to show a significant increase or prolongation of therapeutic effect (Harris and Galin, 1970; Drance and Nash, 1971) . Also, increased viscosity of the ophthalmic solution administered only twice daily did not give adequate control for clinical usefulness (Quigley and Pollack, 1977) .
A prolongation of therapeutic effect, however, can be achieved by sustained release of pilocarpine to the ocular tissues. This is possible only when release of the drug from its vehicle is rate-limiting (Sieg and Robinson, 1977) .
Piloplex emulsion, which contains a new pilocarpine polymer salt, has been designed to give sustained release of pilocarpine. This characteristic of Piloplex has been demonstrated in vitro by comparing the release patterns of pilocarpine hydrochloride with Piloplex. The results, summarised in The medium was an agitated isotonic saline solution (pH 7 1) maintained at 37°C. Active ingredient was determined spectrophotometrically (Ticho et al., 1978) active ingredient from Piloplex is 6 hours, against 1 hour for the corresponding pilocarpine hydrochloride solutions. Preliminary clinical trials on 68 patients with glaucoma treated with Piloplex confirmed its 45 prolonged hypotensive effect (Ticho et al., 1978; Blumenthal et al., 1979) . In these studies Piloplex administered twice daily induced a lower average diurnal intraocular pressure (IOP) level with fewer IOP fluctuations than pilocarpine hydrochloride administered 4 times daily (Fig. 2) . The total daily amount of pilocarpine applied in the two different medications was equal. The present paper reports on the therapeutic effect and safety of long-term Piloplex medication.
Patients and methods
The study was carried out at 3 different glaucoma units. At the Hadassah, Sheba, and Rambam hospitals in Israel 30 eyes of 15 patients who agreed to participate in this survey with their informed consent were studied. All patients had bilateral open-angle glaucoma with visual field defects. All had been under our medical supervision for at least 2 years before this study. Ten of our patients were males and 5 were females. They were aged 48 to 84 except for 1 patient who was 18 years old. The study was divided into two periods: (1) Two-week period in which the patients were treated with their prestudy medications. These medications consisted of pilocarpine hydrochloride (PHCI) 2 % or 4 % 4 times daily, which contains 1-7 and 3-4 % pilocarpine base. To 5 patients additional epinephrine borate (1 % of free base) and/or acetazolamide 250 mg were administered twice a day. The detailed prestudy hospitalised patients) on tl hydrochloride 2% 4 times third day of Piloplex 3-4 ti (Blumenthal et al., 1979) (period B) became accustomed to this medication, and subjectively preferred it to PHCI, mainly because of the twice daily regimen. Adverse visual disturbances ady period is illustrated in Fig. 3 . In the 5 were also reported to occur less owing to the fewer ts to whom epinephrine drops were adminis-daily applications of Piloplex. In conclusion, this n addition to Piloplex an anticipated additive study has shown the long-term therapeutic effect was observed, similar to that found with the and safety of Piloplex medication throughout a trial PHCI and epinephrine.
period of 1 year.
No signs of ocular damage followed Piloplex medication. Specifically, no corneal abrasions, conjunctival reactions, or inflammations were observed. One case was excluded owing to a local sensitivity reaction (No. 13), and 1 (No. 4) died of an unrelated cause. Those patients who had undesirable myopia, induced by miotic drugs following Piloplex administration (10/15), reported that Piloplex caused a similar effect to that caused by PHCI during period A. All patients reported that on the Piloplex regimen blurring occurred only once a day (morning dose) instead of 3 times a day while on pilocarpine hydrochloride 4 times daily.
Discussion
In our previous study we demonstrated the slow release of pilocarpine ion from the pilocarpine 
